Background: Although histone deacetylase inhibitors (HDACi) are promising cancer therapeutics regulating proliferation, differentiation and apoptosis, molecular pathways engaged by specific HDAC isoenzymes in cancer are ill defined. Results: In this study we demonstrate that HDAC2 is highly expressed in pancreatic ductal adenocarcinoma (PDAC), especially in undifferentiated tumours. We show that HDAC2, but not HDAC1, confers resistance towards the topoisomerase II inhibitor etoposide in PDAC cells. Correspondingly, the class I selective HDACi valproic acid (VPA) synergises with etoposide to induce apoptosis of PDAC cells. Transcriptome profiling of HDAC2-depleted PDAC cells revealed upregulation of the BH3-only protein NOXA. We show that the epigenetically silenced NOXA gene locus is opened after HDAC2 depletion and that NOXA upregulation is sufficient to sensitise PDAC cells towards etoposide-induced apoptosis. Conclusions: In summary, our data characterise a novel molecular mechanism that links the epigenetic regulator HDAC2 to the regulation of the pro-apoptotic BH3-only protein NOXA in PDAC. Targeting HDAC2 will therefore be a promising strategy to overcome therapeutic resistance of PDAC against chemotherapeutics that induce DNA damage.
Although the incidence of pancreatic ductal adenocarcinoma (PDAC) is only 10 in 10 5 , it is the fourth leading cause of cancer-related death. One reason for the poor prognosis of PDAC is the failure of most conventional treatments. 1 Nearly all neoplastic changes during the development of a normal cell to a cancer cell, such as DNA damage, oncogene activation or cell cycle deregulation, are potent inducers of the programmed cell death pathway. Therefore, overcoming the apoptotic failsafe is observed in many cancers and results in cell-intrinsic apoptotic and therapeutic resistance. 1 2 Resistance towards apoptosis is also a hallmark of PDAC and therefore lowering the apoptotic threshold is a therapeutic goal. 3 Several recent studies demonstrated that a sensitiser (lowering the apoptotic threshold)/inducer (activation of the apoptotic machinery) strategy is a potential approach for a rational molecular-based tumour therapy in PDAC (summarised by Hamacher et al 3 ) .
According to phylogenetic analyses and sequence homology, histone deacetylases (HDACs) can be grouped in class I to IV enzymes. 4 The yeast Rpd3 homologous enzymes HDAC 1, 2, 3 and 8 represent class I, and the Hda1 homologous enzymes HDAC 4, 5, 6, 7, 9 and 10 represent class II HDACs. HDAC11 reveals homology to class I as well as to class II and is therefore grouped in class IV. In contrast to the zinc-dependent catalysis, class III deacetylases (SIRT1-7) use NAD + as co-factor and are not inhibited by HDAC inhibitors (HDACi). HDACs contribute to cancer initiation and progression by the regulation of cell cycle progression, epithelial differentiation, angiogenesis, metastasis and apoptosis. 5 6 Therefore, HDACi are promising anti-cancer agents and are now being investigated in clinical studies or are already approved by the US Food and Drug Administration for the treatment of cutaneous T cell lymphoma (SAHA). 7 In PDAC cells several HDACi were investigated in vitro and found to inhibit proliferation and to induce apoptosis. [8] [9] [10] [11] [12] [13] [14] At the molecular level, upregulation of the cell cycle inhibitors p21 Cip1 and p27 Kip1 and downregulation of the cell cycle promoters cyclin D1, cyclin B, c-myc and the Sphase kinase-associated protein 2 (SKP2) were observed in PDAC cells upon treatment with HDACi, explaining the HDACi-induced inhibition of proliferation. 8 9 12 15 With respect to apoptosis, the anti-apoptotic BCL2 family members MCL1 and BCL-X L were downregulated and the proapoptotic BH3-only proteins BIM, BID and the multi-domain pro-apoptotic BCL2 family member BAX as well as caspase 8 were upregulated upon treatment of PDAC cells with HDACi, contributing to HDACi-induced apoptosis and HDACimediated sensitisation towards chemotherapeutics in PDAC cells. 10 11 13 16 17 Although these diverse molecular changes were described in PDAC cells with the use of various HDACi, which target multiple HDACs, less is known about the non-redundant isoenzyme-specific function of the different HDACs and the pathways engaged in PDAC. In this study we demonstrate that HDAC2 is highly expressed in PDAC and mediates therapeutic resistance by contributing to the epigenetic silencing of the pro-apoptotic NOXA gene.
MATERIALS AND METHODS Cell culture, luciferase assays, plasmids and reagents
MiaPaCa2, Panc1, BxPc3 and DanG cells were cultivated as described. 15 18 Valproic acid (VPA), etoposide and 5-fluorouracil (5-FU) were from EMD Biosciences (San Diego, California, USA), oxaliplatin was from LC Laboratories (Woburn, Massachusetts, USA) and gemcitabine from Lilly (Indianapolis, Indiana, USA). siRNAs were transfected at a concentration of 50 nmol/l using oligofectamine (Invitrogen, Karlsruhe, Germany). siRNAs were purchased from Eurofins (Ebersberg, Germany). Sequences are available on request. The human NOXA luciferase reporter gene construct was a gift from Dr C Lallemand. 19 Transfections of the NOXA luciferase reporter and luciferase assays were performed as described. 15 
Statistical methods
All data were obtained from at least three independent experiments performed in triplicate and results are presented as the mean and standard error of the mean. To demonstrate statistical significance a two-tailed Student t test was used. p Values are indicated and * denotes a p value of at least ,0.05. IC 50 values were calculated with GraphPad Prism4 using a nonlinear regression model.
Quantitative reverse-transcriptase polymerase chain reaction
Total RNA was isolated from pancreatic carcinoma cell lines using the RNeasy kit (Qiagen, Hilden, Germany). Quantitative mRNA analyses were performed as previously described using real-time polymerase chain reaction (PCR) analysis. 18 Primer sequences are available on request.
Cell lysates and western blot
Whole cell lysates were prepared and western blots were done as recently described. 18 The following antibodies were used: HDAC2 (Santa Cruz, Santa Cruz, California, USA), NOXA and MCL1 (Alexis Biochemicals, San Diego, California, USA), cleaved poly (ADP-ribose) polymerase family, member 1 (PARP; BD Biosciences, Heidelberg, Germany), HDAC1 (Upstate, Billerica, Massachusetts, USA) and b-actin (Sigma-Aldrich, Munich, Germany).
BrdU incorporation, MTT and caspase 3/7 assays
Bromodeoxyuridine (BrdU) incorporation and MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were performed using a colorimetric BrdU and MTT assay (Roche Applied Science, Mannheim, Germany). Caspase 3/7 activity was determined using Promega's Caspase Glo 3/7 assay (Promega, Madison, Wisconsin, USA) according to the manufacturer's instructions.
Gene expression profiling
Gene expression profiling was performed as described. 18 Fortyeight hours after the transfection of a control and a HDAC2specific siRNA, duplicates of total RNA were prepared using an RNeasy Kit (Qiagen). Labelled cRNA was produced and hybridised onto the Affymetrix GeneChip Human Genome U133 Plus 2.0 set according to Affymetrix standard protocols (Affymetrix, Santa Clara, California, USA). Expression data were analysed using Microarray Suite 5.0. Genes known to contribute to the regulation of apoptosis are presented in table 1.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed as described. 18 The antibodies used were: rabbit polyclonal IgG as negative control, anti-HDAC2 and anti-RNA polymerase II (Santa Cruz Biotechnology, Santa Cruz, California, USA) and anti-acetyl-histone H3 (Upstate). To ensure linearity, 28-38 cycles were performed, and one representative result out of at least three independent experiments is shown. Primer sequences are available on request.
Immunohistochemistry
The tissue microarray containing normal and PDAC tissue specimens was purchased from BioCat (Heidelberg, Germany). Immunohistochemistry was performed as described. 20 For HDAC2 immunodetection, formalin-fixed paraffin-embedded tissue sections were dewaxed and placed in a microwave (10 min, 600 W) to recover antigens before incubation with the primary HDAC2 antibody (1:100; Santa Cruz). Primary antibody was followed by a secondary antibody conjugated to biotin (Vector Laboratories, Burlingame, California, USA). Peroxidase conjugated streptavidin was used with 3,39-diaminobenzidine tetrahydrochloride (Sigma) as chromogen. HDAC2 expression was scored in normal pancreatic tissue and PDAC by two independent observers (DS and GS). A final score (0-300) was established by multiplying the percentage of nuclear HDAC2 labelled cells (0-100%) (five high-power fields; magnification, 6400) with the staining intensity (1, low; 2, moderate; 3, strong staining).
HDAC2 gene expression: microarray dataset
The Ishikawa microarray data set (GEO accession number: GSE1542) was accessed using the Oncomine TM Database. The dataset was prepared from pancreatic ductal cell samples, cytologically diagnosed as grade I or II (three samples), grade III (10 samples), grade IV (five samples) or grade V (six samples). 21 
RESULTS

HDAC2 is over-expressed in PDAC
To investigate HDAC2 expression in PDAC we performed HDAC2 immunohistochemistry using human tissue microarrays. In normal pancreas, the acinar compartment and islets of Langerhans stain positive for nuclear HDAC2 ( fig 1A) . . Scoring of nuclear HDAC2 expression revealed a significant 2.2-fold upregulation of HDAC2 in PDAC compared to normal duct epithelium (p = 0.006) ( fig 1C) . Upregulation of HDAC2 was notably observed in G3 tumours (3.1-fold) (p = 0.038) ( fig 1D) . To further validate these expression data, we analysed microarray data published by Ishikawa et al. 21 As shown in fig 1E, HDAC2 mRNA expression gradually increases according to the cytological grade, being highest in PDAC (cytological grade V).
HDAC2 is dispensable for viability and proliferation
To investigate HDAC2 function in PDAC cells, we used RNAi. Figure 2A demonstrates the knockdown of HDAC2 48 and 72 h after transfection of MiaPaCa2 and Panc1 cells with a HDAC2 siRNA. HDAC1 protein expression was not downregulated in HDAC2 siRNA-transfected cells, demonstrating specificity (fig 2A) . In viability assays over a time course of 72 h, no significant reduction of viability in HDAC2-depleted MiaPaCa2 and Panc1 cells compared to control cells was observed ( fig 2B) . Furthermore, BrdU incorporation was not significantly altered up to 72 h after transfection of the HDAC2 siRNA into MiaPaCa2 and Panc1 cells, suggesting that loss of HDAC2 in PDAC cells can be compensated with respect to survival and proliferation ( fig 2C) .
Loss of HDAC2 sensitises towards etoposide
Since HDACs contribute to therapeutic resistance of cancer cells, we tested the sensitivity of HDAC2-depleted MiaPaCa2 and Panc1 cells towards intrinsic inducers of apoptosis. 6 
Valproic acid sensitises towards etoposide
To validate the RNAi results, we used the HDACi valproic acid (VPA), since VPA is a class I-specific HDACi and known to deplete HDAC2 via the proteasome. 22 3) . These data confirmed the observations obtained with the HDAC2 siRNA, suggesting that HDAC2 inhibition results in specific sensitisation towards DNA damage-induced apoptosis.
HDAC2 controls NOXA gene expression
To find genes involved in the observed sensitisation towards intrinsic apoptosis we performed transcriptome profiling. Table 1 shows regulation of genes with known function in apoptosis. Among these genes, only the NOXA gene was significantly upregulated in MiaPaCa2 as well as in Panc1 cells after the HDAC2 knockdown. Since NOXA is involved in the apoptotic initiation upon etoposide treatment, we focused on its role in HDAC2-dependent sensitisation towards etoposide. 24 6A) . Also, VPA treatment induced NOXA mRNA expression in both cell lines in a dose-dependent manner ( fig 6B) . As control, regulation of HDAC2 mRNA upon VPA treatment reached no statistical significance in both cell lines ( fig 6B) . Furthermore, NOXA mRNA expression was only marginally induced in PDAC cells after HDAC1 knockdown (supplementary fig 4) . The VPAinduced increase of NOXA mRNA was paralleled by an equal increase of NOXA promoter activity ( fig 6C) . In ChIP assays direct and specific binding of HDAC2 to the NOXA locus in MiaPaCa2 and Panc1 cells was observed ( fig 6D) . Furthermore, we observed increased binding of acetylated histone H3 and RNA polymerase II to the NOXA promoter 48 h after HDAC2 depletion in MiaPaCa2 and Panc1 cells, arguing for an open chromatin structure and transcriptional upregulation. No change in binding of acetylated histone H3 or RNA polymerase II to the glyceraldehydl-3-phosphate dehydrogenase (GAPDH) promoter was observed, demonstrating specificity ( fig 6D) .
Fitting to an open NOXA locus, we discovered pronounced and accelerated etoposide-induced NOXA mRNA expression in HDAC2-depleted MiaPaCa2 and Panc1 cells in a time-dependent manner ( fig 6E) .
NOXA is essential for HDAC2-dependent resistance towards etoposide
To prove the essential role of NOXA for the sensitisation towards etoposide-induced apoptosis after the HDAC2 knockdown, we transfected HDAC2 and NOXA siRNAs alone or in combination into MiaPaCa2 and Panc1 cells. Knockdown of HDAC2 and NOXA was verified by western blot (fig 7D) . Again, the apoptotic fraction in MiaPaCa2 and Panc1 cells was increased after the knockdown of HDAC2 in etoposide treated cells ( fig 7A) . When HDAC2 and NOXA were simultaneously depleted, the etoposide-induced apoptotic fraction was equal to the fraction of etoposide-treated control siRNA-transfected cells ( fig 7A) . To further validate these results, we performed MTT and caspase 3/ 
DISCUSSION
Although HDACs contribute to the carcinogenesis of solid tumours, definitive HDAC-controlled molecular pathways that allow assessment of relevant biological responses and isoenzyme specific functions as a basis for the improvement of isoenzyme selectivity of future HDACi are ill defined. In this study, we characterised a novel HDAC2-dependent pathway, where HDAC2mediated silencing of the NOXA gene contributes to resistance against topoisomerase II inhibitor treatment in PDAC cells. As in other gastrointestinal tumours, such as colon and gastric cancer, we demonstrate over-expression of HDAC2 in human PDAC. [26] [27] [28] [29] Furthermore, we observed increased nuclear HDAC2 expression already in pancreatic intraepithelial neoplasias (PanINs) in a murine Kras G12D -dependent PDAC model (data not shown). Therefore, over-expression of HDAC2 suggests a key role of HDAC2 in gastrointestinal carcinogenesis. Consistently, an essential contribution of HDAC2 towards the carcinogenesis of gastrointestinal tumours was recently proved in an APC min mouse model of colon cancer in vivo. 30 The functions of HDAC2 are highly cell type and tissue specific. In vivo, a recent report demonstrates that HDAC2 knockout mice are characterised by increased cardiac cell proliferation and apoptosis, a phenotype that was not observed in non-cardiac tissues. 31 In contrast to in vitro studies in various cancer cell lines, we did not find reduced proliferation, cell viability or increased apoptosis upon RNAi-mediated HDAC2 depletion, arguing for a redundant function of HDAC2 towards cell cycle progression and apoptosis induction in PDAC cells. 26 27 29 32 33 The observation that treatment of PDAC cells with the more class I-restricted HDACi VPA has no effect on proliferation and viability points to a contribution of class II or IV HDACs.
As a non-redundant function of HDAC2 we observed a marked sensitisation towards the topoisomerase II inhibitor etoposide, since sensitisation towards etoposide was not observed in HDAC1 siRNA-transfected PDAC cells. This notion is also suggested by the almost identical induction of NOXA mRNA expression in HDAC2 siRNA-transfected and VPAtreated PDAC cells. In addition to the sensitising effect towards etoposide, recent evidence suggests a synergy of HDAC2 depletion with antihormone therapy in breast cancer cells and with death-receptor activation in colon cancer cells, demonstrating the importance of HDAC2 as a therapeutic target. 34 35 The synergy of the class I HDACi/topoisomerase II inhibitor combination in vitro and in vivo is well documented and antitumour activity was observed in a recent phase I trial in advanced solid tumours using VPA and epirubicin. Nevertheless, the molecular mechanisms explaining the synergy and the contributing HDAC isoenzymes are ill defined. [36] [37] [38] [39] Our results now demonstrate that the NOXA gene is an important downstream target explaining the mode of action of the HDACi/topoisomerase II inhibitor combination at the molecular level in PDAC cells. In transcriptome profiling experiments we found an upregulation of the mRNA of the BH3-only protein NOXA in HDAC2-depleted PDAC cells. Furthermore, increased NOXA mRNA expression was also observed after VPA treatment. BH3-only proteins, receptors of cellular stress and most apical regulators of apoptosis, induce, once activated, mitochondrial membrane permeabilisation and the release of pro-apoptotic factors. 40 Since HDAC2 depletion-mediated sensitisation towards etoposide is completely impeded by the RNAi-induced knockdown of NOXA, HDAC2-mediated regulation of the NOXA gene is sufficient to explain the observed synergism. In this pathway, the NOXA gene locus is controlled by HDAC2, since HDAC2 depletion results in specific acetylation of histone H3 at the NOXA locus, demonstrating opening of the chromatin. NOXA was identified as a phorbol ester-inducible and p53regulated gene that is involved in apoptosis upon genotoxic stress. 41 42 This was validated in mouse embryonic fibroblasts of NOXA-deficient mice, which demonstrate a higher threshold for etoposide-induced apoptosis. 24 25 Furthermore, adenoviral transfer of wild-type p53 combined with HDACi treatment synergises to induce NOXA protein expression and apoptosis in the gastric cancer cell line MKN45, suggesting that NOXA expression is epigenetically silenced in an HDAC-dependent manner, and validating the importance of p53 in NOXA gene activation. 43 Since HDAC2 can repress DNA binding of p53 to relevant target genes in MCF7 cells, a p53-dependent activation of NOXA after the HDAC2 knockdown has to be considered in our model system. 33 Nevertheless, this scenario is unlikely, since MiaPaCa2 as well as Panc1 cells express p53 proteins with mutations in the DNA-binding domain. The relevant transcription factors in our model system are unknown so far and ongoing experiments beyond the scope of the current manuscript try to address this topic.
Recent investigations demonstrate an upregulation of NOXA protein and mRNA abundance after treatment of leukaemic cells with HDACi and the contribution of NOXA for HDACi-induced apoptosis. 44 45 In contrast to these studies, we observed no overt induction of apoptosis in HDAC2-depleted or VPA-treated PDAC cells, which might be explained by differences in carcinogenesis and tumour biology of leukaemia and PDAC. Furthermore, the lack of correlation between increased NOXA mRNA and protein observed in MiaPaCa2 cells and the lack of depletion of the MCL1 protein in Panc1 cells after HDAC2 depletion might explain the observation that only HDAC2 targeting fails to induce apoptosis.
Although VPA is less potent than newer generation HDACi, the well-known toxicity profile, long-term safety data, cost-effectiveness and good tissue penetrance argue for testing VPA in further clinical trials, especially in combination with cytotoxic drugs. 46 Since our data demonstrate that NOXA is a relevant HDACi target, NOXA activating agents, like topoisomerase II inhibitors or proteasome inhibitors, should be considered for the design of novel VPA/HDACi combinations. This is especially important Figure 6 HDAC2 represses the NOXA gene. (A) Quantitative NOXA and HDAC2 mRNA expression analysis in MiaPaCa2 (left graph) and Panc1 cells (right graph) after HDAC2 siRNA transfection. Total RNA was prepared 48 h post-transfection. NOXA and HDAC2 mRNA levels were quantified using real-time PCR analysis and normalised to cyclophilin expression levels. (B) Quantitative NOXA and HDAC2 mRNA expression analysis in MiaPaCa2 (left graph) and Panc1 cells (right graph) after VPA treatment. Total RNA was prepared 48 h after the treatment with VPA as indicated. NOXA and HDAC2 mRNA levels were quantified using real-time PCR analysis and normalised to cyclophilin expression levels. (C) NOXA-Luc reporter gene (500 ng) was transfected into MiaPaCa2 (left graph) and Panc1 cells (right graph). Twenty-four hours after the transfection the cells were treated with VPA as indicated or were left as an untreated control. Twenty-four hours after the VPA treatment, luciferase activity was measured (Student t test: *p,0.05 vs control). (D) Chromatin immunoprecipitation analysis of the NOXA gene. Chromatin of MiaPaCa2 (left graph) and Panc1 cells (right graph) transfected with a control siRNA or a HDAC2-specific siRNA was immunoprecipitated with a HDAC2-, a RNA polymerase II-or an acetylated-histone H3-specific antibody or IgG as negative control. Precipitated DNA or 10% of the chromatin input was amplified with gene specific primers for NOXA or GAPDH as a control. (E) Quantitative NOXA mRNA expression analysis in MiaPaCa2 (left graph) and Panc1 cells (right graph). Forty-eight hours after the HDAC2 or control siRNA transfection, cells were treated with 25 mg/ml etoposide or were left as an untreated control. Total RNA was prepared at the indicated time points and NOXA mRNA levels were quantified using real-time PCR analysis and normalised to cyclophilin expression levels. HDAC, histone deacetylase; PCR, polymerase chain reaction; VPA, valproic acid. since we were not able to demonstrate synergy between HDAC2 depletion or VPA treatment with current standard chemotherapeutics, such as gemcitabine or 5-FU.
Together, we have characterised a novel HDAC2-and NOXAdependent pathway of therapeutic resistance in PDAC, which may be the basis for the development of novel therapeutic strategies. Figure 7 NOXA is essential for HDAC2 knockdown-dependent sensitisation towards etoposide. (A) MiaPaCa2 (upper graph) and Panc1 cells (lower graph) were transfected with a control siRNA, a HDAC2-specific siRNA or co-transfected with a HDAC2-and NOXA-specific siRNAs as indicated. Forty-eight hours after the transfection the cells were treated with increasing doses of etoposide, as indicated, for an additional 24 h or left as an untreated control. Apoptotic cells were quantified by fluorescence microscopy after Hoechst staining (Student t test: *p,0.05 vs controls). (B) MiaPaCa2 (left graph) and Panc1 cells (right graph) were transfected with a control siRNA, a HDAC2-specific siRNA or co-transfected with HDAC2and NOXA-specific siRNAs as indicated. Twenty-four hours after the transfection the cells were treated with 12.5 mg/ml etoposide for an additional 48 h or left as an untreated control. Etoposide-induced reduction of viability was measured using MTT assays (Student t test: *p,0.05 vs controls). (C) MiaPaCa2 (left graph) and Panc1 cells (right graph) were transfected with a control siRNA, a HDAC2-specific siRNA or co-transfected with HDAC2and NOXA-specific siRNAs as indicated. Forty-eight hours after the transfection the cells were treated with 25 mg/ml etoposide for an additional 24 h or left as an untreated control. Caspase activity was measured using caspase 3/7 activity assays (Student t test: *p,0.05 vs controls). (D) MiaPaCa2 (upper panel) and Panc1 cells (lower panel) were transfected with a control siRNA, a HDAC2-specific siRNA or co-transfected with HDAC2-and NOXAspecific siRNAs as indicated. Forty-eight hours after the transfection the cells were treated with 25 mg/ml etoposide for an additional 24 h or left as an untreated control. Western blot analysis demonstrates expression of cleaved PARP, HDAC2, MCL1 and NOXA. b-Actin controls equal protein loading. HDAC, histone deacetylase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
